Elisabetta Bacchi, Carlo Negri, Giovanni Targher, Niccolò Faccioli, Massimo Lanza, Giacomo Zoppini, Elisabetta Zanolin, Federico Schena, Enzo Bonora, Paolo Moghetti – 16 March 2013 – Although lifestyle interventions are considered the first‐line therapy for nonalcoholic fatty liver disease (NAFLD), which is extremely common in people with type 2 diabetes, no intervention studies have compared the effects of aerobic (AER) or resistance (RES) training on hepatic fat content in type 2 diabetic subjects with NAFLD.

Christine Schwienbacher, Alice Serafin, Alessandra Zanon, Peter P. Pramstaller, Irene Pichler, Andrew A. Hicks – 16 March 2013

Ryan M. Kwok, Dawn M. Torres, Stephen A. Harrison – 16 March 2013 – Vitamin D is a secosteroid with known effects on calcium homeostasis that has recently been shown to have other significant functions regarding immune modulation, cell differentiation and proliferation, and the inflammatory response. As our understanding of the many functions of vitamin D has grown, the presence of vitamin D deficiency (VDD) has become more evident in Western populations. Concomitantly, nonalcoholic fatty liver disease (NAFLD) has become the most common cause of chronic liver disease.

Ying Wang, Chang Han, Lu Lu, Susan Magliato, Tong Wu – 16 March 2013 – Hedgehog (Hh) signaling plays an important role in embryonic development and in the regulation of a variety of cellular functions. Aberrant activation of Hh signaling has been implicated in several human cancers including hepatocellular carcinoma (HCC). In this study we examined the pathobiological functions and molecular mechanisms of the Hh signaling pathway in HCC cells.

Johann Guillemot, Nabil G. Seidah – 16 March 2013

Miriam B. Vos – 15 March 2013

Mei‐Hsuan Lee, Hwai‐I. Yang, Jessica Liu, Richard Batrla‐Utermann, Chin‐Lan Jen, Uchenna H. Iloeje, Sheng‐Nan Lu, San‐Lin You, Li‐Yu Wang, Chien‐Jen Chen, R.E.V.E.A.L.‐HBV Study Group – 15 March 2013 – Integrating host and HBV characteristics, this study aimed to develop models for predicting long‐term cirrhosis and hepatocellular carcinoma (HCC) risk in chronic hepatitis B virus (HBV) patients.

Sarah Larney, Hannah Kopinski, Curt G. Beckwith, Nickolas D. Zaller, Don Des Jarlais, Holly Hagan, Josiah D. Rich, Brenda J. Bergh, Louisa Degenhardt – 15 March 2013 – People detained in prisons and other closed settings are at elevated risk of infection with hepatitis C virus (HCV). We undertook a systematic review and meta‐analysis with the aim of determining the rate of incident HCV infection and the prevalence of anti‐HCV among detainees in closed settings. We systematically searched databases of peer‐reviewed literature and widely distributed a call for unpublished data.

Mark S. Sulkowski, Marc Bourlière, Jean‐Pierre Bronowicki, Tarik Asselah, Jean‐Michel Pawlotsky, Stephen D. Shafran, Stanislas Pol, Stefan Mauss, Dominique Larrey, Yakov Datsenko, Jerry O. Stern, George Kukolj, Joseph Scherer, Gerhard Nehmiz, Gerhard G. Steinmann, Wulf O. Böcher – 15 March 2013 – Faldaprevir (BI 201335) is a potent, hepatitis C virus (HCV) NS3/4A protease inhibitor.

Christophe Rodriguez, Stéphane Chevaliez, Paul Bensadoun, Jean‐Michel Pawlotsky – 15 March 2013 – Hepatitis B virus (HBV) resistance to nucleoside/nucleotide analogs is frequent. Ultra‐deep pyrosequencing (UDPS) is a powerful new tool that can detect minor viral variants and characterize complex quasispecies mixtures. We used UDPS to analyze the dynamics of adefovir‐resistant HBV variants in patients with chronic HBV infection in whom adefovir resistance occurred during treatment. Amino acid substitutions known to confer resistance to adefovir were detected at baseline in most patients.